Pfizer PFE announced that it is discontinuing the development of danuglipron, its investigational oral GLP-1 receptor agonist (GLP-1 RA), which is being developed to treat obesity. The decision ...

A significant percentage of patients with RA and ANCA positivity were also diagnosed with AAV, with GPA being the most common subtype.

I still remember when a patient woke up from hip surgery in tears—tears of relief. She had been terrified of waking up groggy and overwhelmed by narcotics, a stark contrast to her previous experience.

Supervised lifestyle intervention from a medical professional may help maximize fat loss and minimize muscle tissue loss in people taking the potent weight loss drugs.

A cross-sectional analysis of firearm injury-related emergency department (ED) visits found that between 2018 and 2023, there was approximately one firearm injury ED visit every 30 minutes in the 10 ...

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.